<p><em>扩展合作继续利用 Congruence 的专有计算药物发现引擎 Revenir™，以在神经学和免疫学领域提供开发候选药物</em></p>
<p><em>Congruence 将获得未披露的预付款以及研发资金、里程碑付款和版税</em></p>
<p>, /PRNewswire/ -- 小野制药株式会社（总部：日本大阪；总裁兼首席运营官：高野透；&#34;小野&#34;）与 Congruence Therapeutics 今天宣布，他们通过执行一项新的研究合作协议，扩大了现有的多靶点研究合作伙伴关系，增加了两个额外的项目。</p>
<p>扩展合作的重点是两个在神经学和免疫学领域经过临床验证的高价值靶点，Congruence 将主导发现小分子调节剂并将其推进到开发候选药物阶段。小野将有机会获得独家全球权利，以进一步开发和商业化根据新协议生成的开发候选药物。</p>
<p>两家公司之间的原始合作始于 2024 年 12 月，重点是利用 Congruence 的专有计算引擎 Revenir™，发现针对难以药物化的癌症靶点突变体的新型小分子修正剂。</p>
<p>&#34;我们很高兴能够与小野扩大合作关系，这是一家全球创新药物的先驱，&#34;Congruence 的首席科学官 Sharath Hegde 博士表示。&#34;此次扩展证明了我们在现有合作中所做出的重大贡献，以及我们与小野之间不断建立的信任和信心。我们期待利用双方组织的互补优势，推动重要研究，以造福患者。&#34;</p>
<p>新的合作继续利用 Congruence 的计算药物发现引擎 Revenir™，该引擎系统性地捕捉不同功能状态下蛋白质的生物物理特征，以实现小分子发现的高度差异化方法。</p>
<p>Congruence 针对 MC4R 缺乏的遗传性肥胖的全资项目本月进入 1/1b 期临床研究。在接下来的几周内，Congruence 还将为其针对 GBA1 驱动的帕金森病和α1-抗胰蛋白酶缺乏症的每个项目提名开发候选药物。</p>
<p>&#34;Congruence 的先进计算发现引擎正吸引越来越多的全球关注，其主导项目进入临床开发。我们很荣幸与 Congruence 的持续合作正在扩展到包括神经学和免疫学在内的其他优先领域，&#34;小野的企业官/执行董事、发现与研究部的 Seishi Katsumata 表示。&#34;通过这一合作关系，我们将致力于加速药物开发，以便尽快为有未满足医疗需求的患者提供创新的新药。&#34;</p>
<p>根据今天宣布的新协议，Congruence 将获得预付款，并有资格在发现、开发、批准和商业化的某些里程碑达成时获得额外付款——此外，还将根据相关产品的年度净销售额获得分级版税。此外，小野将报销 Congruence 在扩展合作中所产生的内部和外部研究费用。</p>
<p><strong>关于 Revenir™药物发现平台</strong></p>
<p>Revenir™是 Congruence 的专有计算药物发现平台，捕捉蛋白质在不同功能状态下的动态生物物理变化，提供对蛋白质功能及其调节的独特见解。通过检查表面特征和一系列生物物理描述符，Revenir™预测小分子诱导的基础生理蛋白状态的调节。该平台驱动的策略支撑了 Congruence 日益增长的首创和最佳项目管线，针对与显著未满足医疗需求相关的基因验证靶点，支持一个易于扩展和可重复的价值创造范式。</p>
<p><strong>关于 Congruence Therapeutics</strong></p>
<p>Congruence 是一家以计算为驱动的生物技术公司，正在建立一条独特的转化小分子修正剂管线，合理设计以恢复异常蛋白功能。我们的专有可扩展平台 Revenir™捕捉蛋白质在其构象集合中的生物物理特征，以识别新型别构和隐秘口袋，这些口袋经过虚拟筛选以生成新化学物质。Congruence 利用其专有发现引擎推出了一条针对高价值、基因验证、难以药物化靶点的全资药物管线，涵盖包括遗传性肥胖、GBA 帕金森病和α1-抗胰蛋白酶缺乏症在内的多种适应症。Congruence 还在进一步部署其发现平台，以支持与大型制药公司进行的多靶点研究合作，专注于发现小分子修正剂和别构调节剂，用于治疗肿瘤学、代谢疾病、神经学和免疫学领域的疾病。</p>
<p><strong>关于小野制药株式会社</strong></p>
<p>小野制药株式会社为全球患者提供创新疗法。秉持 “致力于与疾病和疼痛作斗争” 的理念，小野针对包括肿瘤学、免疫学与炎症以及神经学在内的未满足医疗需求领域，促进与学术界和生物技术组织的合作，以加速药物发现。通过其子公司 Deciphera Pharmaceuticals，小野正在加速在美国和欧洲的临床开发和商业运营，以推动全球业务扩展并进一步承诺于患者护理。有关更多信息，请访问公司网站 https://www.ono-pharma.com/en。</p>
<p><strong>公司联系方式</strong> 查尔斯·格鲁布斯坦</p>
<p>首席运营官</p>
<p>[email protected]</p>
<p><strong>媒体联系方式</strong> 艾米·康拉德</p>
<p>Juniper Point</p>
<p>[email protected]</p>
<p>858-366-3243</p>
<p>来源：Congruence Therapeutics</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9Tlk5OTQ1NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIxNzAwUFJfTkVXU19VU1BSX19fX19OWTk5NDU3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9Tlk5OTQ1NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIxNzAwUFJfTkVXU19VU1BSX19fX19OWTk5NDU3"/></p>

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

<p>小野制药与 Congruence Therapeutics 扩大了他们的多靶点研究合作伙伴关系，新增了两个专注于神经学和免疫学的新项目。Congruence 将主导小分子调节剂的发现，而小野制药则有权选择独家全球开发和商业化这些候选药物的权利。此次合作利用了 Congruence 的 Revenir™计算药物发现引擎。Congruence 将获得预付款、里程碑付款以及基于净销售额的版税。该合作旨在加速满足未满足医疗需求患者的药物开发</p>

<p><em>Expanded collaboration continues to leverage Congruence's proprietary computational</em> <em>drug discovery engine, Revenir™ to deliver Development Candidates in Neurology and Immunology</em></p>
<div class="lb-trans"><p><em>扩展合作继续利用 Congruence 的专有计算药物发现引擎 Revenir™，以在神经学和免疫学领域提供开发候选药物</em></p>
</div><p><em>Congruence to receive undisclosed upfront payment as well as R&amp;D funding, milestones and royalties</em></p>
<div class="lb-trans"><p><em>Congruence 将获得未披露的预付款以及研发资金、里程碑付款和版税</em></p>
</div><p>, /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; &#34;Ono&#34;) and Congruence Therapeutics today announced that they have expanded their existing multi-target research partnership through the execution of a new research collaboration for two additional programs.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 小野制药株式会社（总部：日本大阪；总裁兼首席运营官：高野透；&#34;小野&#34;）与 Congruence Therapeutics 今天宣布，他们通过执行一项新的研究合作协议，扩大了现有的多靶点研究合作伙伴关系，增加了两个额外的项目。</p>
</div><p>The expanded collaboration is focused on two clinically validated high-value targets in the areas of neurology and immunology for which Congruence will lead the effort to discover small molecule modulators and advance them to the development candidate stage. Ono will have the option to secure exclusive worldwide rights to further develop and commercialize development candidates generated under the new agreement.</p>
<div class="lb-trans"><p>扩展合作的重点是两个在神经学和免疫学领域经过临床验证的高价值靶点，Congruence 将主导发现小分子调节剂并将其推进到开发候选药物阶段。小野将有机会获得独家全球权利，以进一步开发和商业化根据新协议生成的开发候选药物。</p>
</div><p>An original collaboration between the companies, which began in December 2024, is focused on leveraging Congruence's proprietary computational engine, Revenir™, to discover novel small molecule correctors directed to mutants of a difficult-to-drug cancer target.</p>
<div class="lb-trans"><p>两家公司之间的原始合作始于 2024 年 12 月，重点是利用 Congruence 的专有计算引擎 Revenir™，发现针对难以药物化的癌症靶点突变体的新型小分子修正剂。</p>
</div><p>&#34;We are excited to expand our partnership with Ono, a global pioneer of innovative medicines,&#34; said Sharath Hegde PhD, Chief Scientific Officer of Congruence. &#34;The expansion is a testament to the significant contributions we have made in our existing collaboration as well as the trust and confidence we continue to build with Ono. We look forward to leveraging the complementary strengths of both organizations to advance important research for the benefit of patients.&#34;</p>
<div class="lb-trans"><p>&#34;我们很高兴能够与小野扩大合作关系，这是一家全球创新药物的先驱，&#34;Congruence 的首席科学官 Sharath Hegde 博士表示。&#34;此次扩展证明了我们在现有合作中所做出的重大贡献，以及我们与小野之间不断建立的信任和信心。我们期待利用双方组织的互补优势，推动重要研究，以造福患者。&#34;</p>
</div><p>The new collaboration continues to leverage Congruence's computational drug discovery engine, Revenir™, which systematically captures the biophysical features of proteins in different functional states to enable a highly differentiated approach to small-molecule discovery.</p>
<div class="lb-trans"><p>新的合作继续利用 Congruence 的计算药物发现引擎 Revenir™，该引擎系统性地捕捉不同功能状态下蛋白质的生物物理特征，以实现小分子发现的高度差异化方法。</p>
</div><p>Congruence's wholly owned program directed to MC4R-deficient genetic obesity is entering a Phase 1/1b clinical study this month. In the next few weeks, Congruence will also nominate development candidates for each of its programs directed to GBA1-driven Parkinson's Disease and Alpha-1 Antitrypsin deficiency.</p>
<div class="lb-trans"><p>Congruence 针对 MC4R 缺乏的遗传性肥胖的全资项目本月进入 1/1b 期临床研究。在接下来的几周内，Congruence 还将为其针对 GBA1 驱动的帕金森病和α1-抗胰蛋白酶缺乏症的每个项目提名开发候选药物。</p>
</div><p>&#34;Congruence's advanced computational discovery engine is attracting growing global attention with its lead program entering clinical development. We are honored that our ongoing collaboration with Congruence is expanding beyond oncology to other priority areas including both neurology and immunology,&#34; said Seishi Katsumata, Corporate Officer / Executive Director, Discovery &amp; Research of Ono. &#34;Through this partnership, we will be committed to accelerating the drug development so that we can deliver innovative new medicines to patients with unmet medical needs as quickly as possible.&#34;</p>
<div class="lb-trans"><p>&#34;Congruence 的先进计算发现引擎正吸引越来越多的全球关注，其主导项目进入临床开发。我们很荣幸与 Congruence 的持续合作正在扩展到包括神经学和免疫学在内的其他优先领域，&#34;小野的企业官/执行董事、发现与研究部的 Seishi Katsumata 表示。&#34;通过这一合作关系，我们将致力于加速药物开发，以便尽快为有未满足医疗需求的患者提供创新的新药。&#34;</p>
</div><p>Under the terms of the new agreement announced today, Congruence will receive an upfront payment and is eligible to receive additional payments upon the achievement of certain milestones in discovery, development, approval and commercialization – in addition to tiered royalties based on annual net sales of related products. Moreover, Ono will reimburse Congruence for the internal and external research costs it incurs in connection with the activities undertaken in the expanded partnership.</p>
<div class="lb-trans"><p>根据今天宣布的新协议，Congruence 将获得预付款，并有资格在发现、开发、批准和商业化的某些里程碑达成时获得额外付款——此外，还将根据相关产品的年度净销售额获得分级版税。此外，小野将报销 Congruence 在扩展合作中所产生的内部和外部研究费用。</p>
</div><p><strong>About Revenir™ Drug Discovery Platform</strong></p>
<div class="lb-trans"><p><strong>关于 Revenir™药物发现平台</strong></p>
</div><p>Revenir™, Congruence's proprietary computational drug discovery platform, captures the dynamic biophysical changes of proteins in different functional states, offering unique insights into protein function and their modulation. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, Revenir™ predicts small molecule induced modulation of underlying physiologic protein states. This platform-driven strategy underpins Congruence's growing pipeline of first-in-class and best-in-class programs directed to genetically validated targets implicated in conditions associated with significant unmet medical need, supporting a readily scalable and repeatable value creation paradigm.</p>
<div class="lb-trans"><p>Revenir™是 Congruence 的专有计算药物发现平台，捕捉蛋白质在不同功能状态下的动态生物物理变化，提供对蛋白质功能及其调节的独特见解。通过检查表面特征和一系列生物物理描述符，Revenir™预测小分子诱导的基础生理蛋白状态的调节。该平台驱动的策略支撑了 Congruence 日益增长的首创和最佳项目管线，针对与显著未满足医疗需求相关的基因验证靶点，支持一个易于扩展和可重复的价值创造范式。</p>
</div><p><strong>About Congruence Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Congruence Therapeutics</strong></p>
</div><p>Congruence is a computationally driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support its multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors and allosteric modulators for the treatment of diseases in oncology, metabolic disease, neurology and immunology.</p>
<div class="lb-trans"><p>Congruence 是一家以计算为驱动的生物技术公司，正在建立一条独特的转化小分子修正剂管线，合理设计以恢复异常蛋白功能。我们的专有可扩展平台 Revenir™捕捉蛋白质在其构象集合中的生物物理特征，以识别新型别构和隐秘口袋，这些口袋经过虚拟筛选以生成新化学物质。Congruence 利用其专有发现引擎推出了一条针对高价值、基因验证、难以药物化靶点的全资药物管线，涵盖包括遗传性肥胖、GBA 帕金森病和α1-抗胰蛋白酶缺乏症在内的多种适应症。Congruence 还在进一步部署其发现平台，以支持与大型制药公司进行的多靶点研究合作，专注于发现小分子修正剂和别构调节剂，用于治疗肿瘤学、代谢疾病、神经学和免疫学领域的疾病。</p>
</div><p><strong>About Ono Pharmaceutical Co., Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于小野制药株式会社</strong></p>
</div><p>Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of &#34;Dedicated to the Fight against Disease and Pain,&#34; Ono targets areas with unmet medical needs including oncology, immunology &amp; inflammation, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.</p>
<div class="lb-trans"><p>小野制药株式会社为全球患者提供创新疗法。秉持 “致力于与疾病和疼痛作斗争” 的理念，小野针对包括肿瘤学、免疫学与炎症以及神经学在内的未满足医疗需求领域，促进与学术界和生物技术组织的合作，以加速药物发现。通过其子公司 Deciphera Pharmaceuticals，小野正在加速在美国和欧洲的临床开发和商业运营，以推动全球业务扩展并进一步承诺于患者护理。有关更多信息，请访问公司网站 https://www.ono-pharma.com/en。</p>
</div><p><strong>Company Contact</strong> Charles Grubsztajn</p>
<div class="lb-trans"><p><strong>公司联系方式</strong> 查尔斯·格鲁布斯坦</p>
</div><p>Chief Operating Officer</p>
<div class="lb-trans"><p>首席运营官</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>Media Contact</strong> Amy Conrad</p>
<div class="lb-trans"><p><strong>媒体联系方式</strong> 艾米·康拉德</p>
</div><p>Juniper Point</p>
<div class="lb-trans"><p>Juniper Point</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>858-366-3243</p>
<div class="lb-trans"><p>858-366-3243</p>
</div><p>SOURCE Congruence Therapeutics</p>
<div class="lb-trans"><p>来源：Congruence Therapeutics</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMzAyJk5ld3NJdGVtSWQ9Tlk5OTQ1NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAzMDIxNzAwUFJfTkVXU19VU1BSX19fX19OWTk5NDU3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY99457&amp;Transmission_Id=202603021700PR_NEWS_USPR_____NY99457&amp;DateId=20260302"/></p>

17:00 ETCongruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs

prnewswire

医疗业 ETF - Vanguard

小野制药(ADR)

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

ONO Pharmaceutical Co., Ltd.

美国制药 ETF - iShares

Invesco Nasdaq Biotechnology ETF

医药突破 ETF - ALPS

17:00 ET Congruence 与小野制药 (ADR) 通过新增两个项目来扩展多目标研究合作伙伴关系